These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Integrated contrast-enhanced diagnostic whole-body PET/CT as a first-line restaging modality in patients with suspected metastatic recurrence of breast cancer. Dirisamer A, Halpern BS, Flöry D, Wolf F, Beheshti M, Mayerhoefer ME, Langsteger W. Eur J Radiol; 2010 Feb; 73(2):294-9. PubMed ID: 19181468 [Abstract] [Full Text] [Related]
8. STIR turbo SE MR imaging vs. coregistered FDG-PET/CT: quantitative and qualitative assessment of N-stage in non-small-cell lung cancer patients. Ohno Y, Koyama H, Nogami M, Takenaka D, Yoshikawa T, Yoshimura M, Ohbayashi C, Sugimura K. J Magn Reson Imaging; 2007 Oct; 26(4):1071-80. PubMed ID: 17896365 [Abstract] [Full Text] [Related]
9. 18F-FDG PET/CT as a staging procedure in primary stage II and III breast cancer: comparison with conventional imaging techniques. Koolen BB, Vrancken Peeters MJ, Aukema TS, Vogel WV, Oldenburg HS, van der Hage JA, Hoefnagel CA, Stokkel MP, Loo CE, Rodenhuis S, Rutgers EJ, Valdés Olmos RA. Breast Cancer Res Treat; 2012 Jan; 131(1):117-26. PubMed ID: 21935602 [Abstract] [Full Text] [Related]
10. Usefulness of FDG-PET/CT in the detection of pancreatic metastases from lung cancer. Sato M, Okumura T, Kaito K, Kiyoshima M, Asato Y, Uchiumi K, Iijima H, Hashimoto I, Kaburagi T, Amemiya R. Ann Nucl Med; 2009 Jan; 23(1):49-57. PubMed ID: 19205838 [Abstract] [Full Text] [Related]
11. Fusion of metabolic function and morphology: sequential [18F]fluorodeoxyglucose positron-emission tomography/computed tomography studies yield new insights into the natural history of bone metastases in breast cancer. Du Y, Cullum I, Illidge TM, Ell PJ. J Clin Oncol; 2007 Aug 10; 25(23):3440-7. PubMed ID: 17592153 [Abstract] [Full Text] [Related]